Skip to main content

Corporate insider profile

Deborah J Andrews Insider Trades

Deborah J Andrews has reported 1 open-market purchase on SEC Form 4 and is a net buyer of $20,000 across 1 company. The most recent open-market transaction was reported on Nov 16, 2026. Source: SEC Form 4 filings.

Latest reported as Director of Lineage Cell Therapeutics, Inc. (LCTX).

SEC-reported filing activity is provided for research purposes and is not investment advice.

Purchase filings
1
Reported companies
1
Net open-market value
$20,000
Latest transaction
Nov 16, 2026

Affiliated corporations

Reported company relationships

Transaction history

Open-market Transactions

Open-market insider purchase and sale transactions
DateCompanyRoleTypeSharesPriceTotal value
Nov 16, 2026Lineage Cell Therapeutics, Inc. (LCTX)DirectorOpen Market Purchase25,000$0.80$20,000

Common questions

Deborah J Andrews insider trading FAQ

Is Deborah J Andrews buying or selling stock?
Across all SEC Form 4 open-market filings on record, Deborah J Andrews is a net buyer of $20,000, with 1 open-market purchase reported. The latest transaction was reported on Nov 16, 2026.
Which companies does Deborah J Andrews report insider trades for?
Deborah J Andrews has reported open-market trades in Lineage Cell Therapeutics, Inc. (LCTX). The latest SEC-reported relationship is Director of Lineage Cell Therapeutics, Inc. (LCTX).
Where does Deborah J Andrews's insider trading data come from?
Watch Insiders reads the SEC Form 4 filings submitted to EDGAR under reporting owner CIK 1325697, and refreshes this page daily.